VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Prostate cancer DNA vaccine encoding PSCA
Vaccine Information
  • Vaccine Name: Prostate cancer DNA vaccine encoding PSCA
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0004451
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • Prostate stem cell antigen gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pcDNA3 expressed prostate stem cell antigen (PSCA) (Garcia-Hernandez et al., 2008).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000132
  • Immunization Route: Gene gun
Host Response

Mouse Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Eight-week-old TRAMP mice displaying prostate intraepithelial neoplasia were vaccinated with a heterologous prime/boost strategy consisting of gene gun-delivered PSCA-cDNA followed by Venezuelan equine encephalitis virus replicons encoding PSCA. PSCA-vaccinated TRAMP mice had a 90% survival rate at 12 months of age. In contrast, all control mice had succumbed to prostate cancer or had heavy tumor loads (Garcia-Hernandez et al., 2008).
References
Garcia-Hernandez et al., 2008: Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer research. 2008; 68(3); 861-869. [PubMed: 18245488].